Archive for the Nanoscope Press Release Category

Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality

Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality

Nanoscope Therapeutics Appoints Khandan Baradaran as Senior Vice President of Regulatory and Quality

Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress

Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress

Nanoscope Therapeutics Announces Presentations in Upcoming ASGCT Annual Meeting and Retina World Congress

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Nanoscope Therapeutics Announces Presentations at the ARVO Annual Meeting

Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits

Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits

Nanoscope Therapeutics to Present at the OIS and Retinal Cell and Gene Therapy Innovation Summits

Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor

Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor

Nanoscope Therapeutics Enhances Mutation-Independent Retinal Gene Therapy Programs with Appointment of Allen C. Ho, MD, as Chief Medical Advisor

Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024

Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024

Nanoscope Therapeutics to Present at the World Orphan Drug Congress 2024

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

Nanoscope Therapeutics Announces Positive Top-line Results from Randomized Controlled Trial of MCO-010 for Retinitis Pigmentosa

  • MCO-010 achieved its primary and key secondary endpoints with statistical significance and no serious adverse events
  • Data from the Phase 2b RESTORE trial demonstrate clinically meaningful vision improvement in legally blind individuals with progressive and permanent neurodegeneration of the retina
  • RESTORE is the first randomized, controlled trial of a mutation-agnostic gene therapy for a genetic disease
  • Nanoscope anticipates submitting a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) in the second half of 2024

Nanoscope Therapeutics Announces Participation in Upcoming Conferences

Nanoscope Therapeutics Announces Participation in Upcoming Conferences

Nanoscope Therapeutics Announces Participation in Upcoming Conferences

Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Nanoscope to Moderate Discussions at the 4th Annual Gene Therapy Comparability Summit

Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting

Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting

Nanoscope Announces Presentation at the 68th Annual Biophysical Society Meeting

Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting

Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting

Nanoscope Therapeutics to Present at 47th Annual Macula Society Meeting

Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting

Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting

Nanoscope Therapeutics Announces Presentation at Bascom Palmer Eye Institute’s 21st Annual Angiogenesis, Exudation, and Degeneration Meeting

Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

Nanoscope Therapeutics Provides Regulatory Update on MCO-010 for the Treatment of Retinitis Pigmentosa

Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference

Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference

Nanoscope Therapeutics to Present at the 20th Annual Advanced Therapies Week Conference

Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

New Addition Highlights Continued Enhancement of Organization’s Strategic Trajectory

Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress

Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress

Nanoscope Therapeutics Announces Presentation at the FLORetina 2023 Congress

Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII

Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII

Nanoscope Therapeutics to Present at Ophthalmology Innovation Summit (OIS) XIII

Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

Nanoscope Therapeutics to Present at the 4th Annual Dry AMD Therapeutic Development Summit

Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina at Eyecelerator@AAO 2023

Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina  at Eyecelerator@AAO 2023

Nanoscope Therapeutics Awarded ‘Best of Show’ for Retina at Eyecelerator@AAO 2023

Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023

Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023

Nanoscope Therapeutics Announces Presentations at the American Academy of Ophthalmology Annual Meeting 2023

Nanoscope Therapeutics, Inc.
Trinity Towers
2777 N. Stemmons Fwy.
Dallas, TX 75207
(817) 857-1186
  • Dr. Samarendra Mohanty, PhD |  Co-Founder & President

    Samarendra Mohanty (Co-Founder/President) is an inventor & serial entrepreneur with 20+ years experience in Biomedical Sciences. He is Co-Founder of several Biotechs and Biomedical device /diagnostic companies (developed & commercialized $100K+ biomedical instruments.)

    Samar obtained M.Tech in Applied Optics from the Indian Institute of Technology-Delhi and a PhD in (Bio)Physics from the Indian Institute of Sciences-Bangalore.

    His extensive Biomedical Technologies experience includes serving as Professor/Senior Scientist at the University of Texas;  University of California, Irvine; Center for Adv. Tech (India); Int. Mol. Biotech (Germany); Univ. Pavia (Italy); NUS (Singapore); and University of St. Andrews (UK). He has authored over 200 international patents and publications in leading journals including Nature and Nature Photonics.

    He is the Principal Investigator for major grants from the National Eye Institute including Audacious Goal Initiative and Bioengineering Research grants. He serves on the editorial board of journals and chairs an international conference on optogenetics. He is the winner of a 2019 Healthcare Heroes award (Fort Worth Business Press), Retinal Organoid Challenge Award, Audacious Goal Initiative Award (NIH), Finalist of Tech Titan, and NIH-Director’s Innovator Award.